HealthMap, a team of researchers, epidemiologists and software developers at Boston Children's Hospital founded in 2006, is an established global leader in utilizing online informal sources for disease outbreak monitoring and real-time surveillance of emerging public health threats.
These therapies are effective for treating mild to moderate migraine pain. Specific acute care medications include dihydroergotamine (DHE) and the triptans (sumatriptan, rizatriptan, zolmitriptan, naratriptan, eletriptan, and frovatriptan).These medications both inhibit dilatation of meningeal vessels and reduce abnormal neural activation.he half-life of most of the available medications is approximately 2 to 3 hours; those with longer half-lives (eg, DHE nasal spray, naratriptan, eletriptan, and frovatriptan) have lower recurrence rates (15% to 20% vs 30% for other triptans). Recurrence with triptans tends to occur within 8 to 12 hours.
Rizatriptan (trade name Maxalt) is a 5-HT1 receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches.[1] It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).